Breathtec Biomedical Announces Appointment of CEO
01 March 2018 - 2:00PM
Breathtec Biomedical Inc. (CSE:BTH) (CNSX:BTH) (FRANKFURT:BTI)
(OTCQB:BTHCF) (the “Company”) is pleased to announce the
appointment of Christopher J. Moreau as Chief Executive Officer
effective March 1, 2018.
Mr. Moreau is a seasoned business professional in the life
sciences sector with a strong background in medical devices and
biomarker research. Mr. Moreau is currently the CEO of Nash
Pharmaceuticals Inc, a privately-held drug development company and
was previously President & CEO of Miraculins Inc, a public
company where he raised in excess of C$13 million to fund research
& development for screening tests for prostate cancer, skin
cholesterol and type 2 diabetes.
"The Board is very pleased to welcome Christopher to the
Breathtec team," states Dr. Raj Attariwala, Director of Breathtec.
"After conducting a thorough search, the CEO search committee
concluded that with his extensive industry knowledge and experience
with medical devices and biomarkers, Christopher was ideally suited
to increase shareholder value. Christopher’s hands-on and
results-driven approach will help Breathtec’s development roadmap
as well as explore new potential acquisitions."
The Company also announces that 1,325,000 stock options are
being granted to directors, officers, employees and contractors of
the Company including 500,000 stock options to Mr. Moreau.
The options were assigned an exercise price of $0.24 and are
exercisable for a period of five years, subject to regulatory
approval. These stock options are granted under the Company’s stock
option plan.
ON BEHALF OF THE BOARD “Michael Sadhra” Chief
Financial Officer & Director
ABOUT BREATHTEC BIOMEDICAL INC. Breathtec
Biomedical, Inc. (“Breathtec”) was formed to propel innovative
research in the area of airborne analysis as a medical screening
tool. Our efforts are aimed at leading the development of
commercially viable methods for the early screening of certain
pathogens. Our primary avenue of investigation is focused on
innovation and advances in the field of specialized mass
spectrometry. For more information,
visit www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has
reviewed nor accepts responsibility for the adequacy or accuracy of
the content of this news release. This news release contains
forward-looking statements relating to product development,
licensing, commercialization and regulatory compliance issues and
other statements that are not historical facts. Forward-looking
statements are often identified by terms such as “will”, “may”,
“should”, “anticipate”, “expects” and similar expressions. All
statements other than statements of historical fact, included in
this release are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company’s expectations include the failure to
satisfy the conditions of the relevant securities exchange(s) and
other risks detailed from time to time in the filings made by the
Company with securities regulations. The reader is cautioned that
assumptions used in the preparation of any forward-looking
information may prove to be incorrect. Events or circumstances may
cause actual results to differ materially from those predicted, as
a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company.
The reader is cautioned not to place undue reliance on any
forward-looking information. Such information, although considered
reasonable by management at the time of preparation, may prove to
be incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements as
expressly required by applicable law.
CONTACT:Alfred WongTel: 604 398 8840 ext
700info@breathtechbiomedical.cominvestors@breathtecbiomedical.comwww.breathtecbiomedical.com